TERT and hepatocellular carcinoma: To circumvent this problem, one would need to deliver the components separately, or substitute HCV core with another HCV antigen expressed in chronically infected cancerous liver, or alternatively, design therapeutic vaccines against HCV-related HCC-based solely on TERT.